# TROPiCS-03 (NCT03964727)

> Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03964727
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Gilead Sciences
- Conditions: Metastatic Solid Tumor
- Interventions: Sacituzumab Govitecan-hziy
- Enrollment: 227
- Primary outcome: Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Investigator's Assessment

## Commentary we found

- X threads: 14
- YouTube: 6
- Podcasts: 5

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=tropics-03-nct03964727

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03964727", "email": "<work email>"}; the inbox owner confirms by the emailed link.